Application of Transition-Metal Catalysis, Biocatalysis, and Flow Chemistry as State-of-the-Art Technologies in the Synthesis of LCZ696

LCZ696 is a novel treatment for patients
suffering from heart failure
that combines the two active pharmaceutical ingredients sacubitril
and valsartan in a single chemical compound. While valsartan is an
established drug substance, a new manufacturing process suitable for
large-scale commercial production had to be developed for sacubitril.
The use of chemocatalysis, biocatalysis, and flow chemistry as state-of-the-art
technologies allowed to efficiently build up the structure of sacubitril
and achieve the defined performance targets.